The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple sclerosis (RMS; to include relapsing-remitting MS \[RRMS\] or active secondary progressive MS).
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change in CD3+ T Cells % From Baseline to Week 5
Timeframe: Baseline to Week 5 (5 weeks after first cladribine dose)
Change in CD3+ T Cells % From Baseline to Week 10
Timeframe: Baseline to Week 10 (10 weeks after first cladribine dose)
Change in CD3+ T Cells % From Baseline to Year 1
Timeframe: Baseline to Year 1 (45 weeks after first cladribine dose)
Change in CD3+ T Cells % From Baseline to Year 2
Timeframe: Baseline to Year 2 (45 weeks after last cladribine dose)
Change in CD3+ T Cells Absolute Numbers (Cells/mL) From Baseline to Week 5
Timeframe: Baseline to Week 5
Change in CD3+ T Cells Absolute Numbers (Cells/mL) From Baseline to Week 10
Timeframe: Baseline to Week 10 (10 weeks after first cladribine dose)
Change in CD3+ T Cells Absolute Numbers (Cells/mL) From Baseline to Year 1
Timeframe: Baseline to Year 1 (45 weeks after first cladribine dose)
Change in CD3+ T Cells Absolute Numbers (Cells/mL) From Baseline to Year 2
Timeframe: Baseline to Year 2 (45 weeks after last cladribine dose)
Change in CD19+ B Cells % From Baseline to Week 5
Timeframe: Baseline to Week 5 (5 weeks after first cladribine dose)
Change in CD19+ B Cells % From Baseline to Week 10
Timeframe: Baseline to Week 10 (10 weeks after first cladribine dose)
Change in CD19+ B Cells % From Baseline to Year 1
Timeframe: Baseline to Year 1 (45 weeks after first cladribine dose)
Change in CD19+ B Cells % From Baseline to Year 2
Timeframe: Baseline to Year 2 (45 weeks after last cladribine dose)
Change in CD19+ B Cells Absolute Numbers (Cells/mL) From Baseline to Week 5
Timeframe: Baseline to Week 5 (5 weeks after first cladribine dose)
Change in CD19+ B Cells Absolute Numbers (Cells/mL) From Baseline to Week 10
Timeframe: Baseline to Week 10 (10 weeks after first cladribine dose)
Change in CD19+ B Cells Absolute Numbers (Cells/mL) From Baseline to Year 1
Timeframe: Baseline to Year 1 (45 weeks after first cladribine dose)
Change in CD19+ B Cells Absolute Numbers (Cells/mL) From Baseline to Year 2
Timeframe: Baseline to Year 2 (45 weeks after last cladribine dose)
Change in the Neurofilament Light Chain (NfL) Level From Baseline to Week 5
Timeframe: Baseline to Week 5 (5 weeks after first cladribine dose)
Change in the Neurofilament Light Chain (NfL) Level From Baseline to Week 10
Timeframe: Baseline to Week 10 (10 weeks after first cladribine dose)
Change in the Neurofilament Light Chain (NfL) Level From Baseline to Year 1
Timeframe: Baseline to Year 1 (45 weeks after first cladribine dose)
Change in the Neurofilament Light Chain (NfL) Level From Baseline to Year 2
Timeframe: Baseline to Year 2 (45 weeks after last cladribine dose)